Can Pan-TB shorter regimens be a promising hope for ending TB in India by 2025 in ongoing COVID-19 era?
Indian J Tuberc
.
2022 Oct;69(4):377-382.
doi: 10.1016/j.ijtb.2022.06.006.
Epub 2022 Jun 23.
Authors
Rajendra Prasad
1
,
Abhijeet Singh
2
,
Nikhil Gupta
3
Affiliations
1
Department of Pulmonary Medicine, Era Medical College, Lucknow, Uttar Pradesh, India. Electronic address: rprasadkgmc@gmail.com.
2
Department of Pulmonary & Critical Care Medicine, Fortis Hospital, Vasant Kunj, New Delhi, India.
3
Department of Internal Medicine, Dr Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
PMID:
36460365
PMCID:
PMC9221684
DOI:
10.1016/j.ijtb.2022.06.006
No abstract available
Keywords:
Drug resistant; Drug sensitive; Shorter; Tuberculosis; Universal regimen.
Publication types
Editorial
MeSH terms
COVID-19
Humans
India / epidemiology
Longitudinal Studies
Tuberculosis* / drug therapy
Tuberculosis* / prevention & control